Hereditary angioedema
Drug research and approvals for hereditary angioedema: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 19 studies of hereditary angioedema are recruiting on ClinicalTrials.gov, Health Canada has authorized 41 drug trials for it since 2013, FDA has 16 approved and 4 open orphan designations naming it, and the EU has 9 authorised medicines for it.
- Recruiting worldwide: 19
- Trials authorized in Canada: 41
- FDA orphan approvals: 16
- EU medicines: 9
Recruiting Now
Newest start dates first, of 19 recruiting on ClinicalTrials.gov ↗- A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South KoreaNCT07445087 · Not reported · Takeda · starts Sep 21, 2026
- Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With…NCT07654829 · Phase 4 · KalVista Pharmaceuticals, Ltd. · starts Aug 17, 2026
- A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary AngioedemaNCT07293364 · Not applicable · Takeda · starts May 12, 2026
- Donidalorsen Treatment in Children With Hereditary AngioedemaNCT07298447 · Phase 3 · Ionis Pharmaceuticals, Inc. · starts Apr 21, 2026
- Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)NCT07428499 · Phase 3 · ADARx Pharmaceuticals, Inc. · starts Apr 2, 2026
- Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdemaNCT07448181 · Not reported · Istituti Clinici Scientifici Maugeri SpA · starts Feb 23, 2026
- Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of…NCT07266805 · Phase 3 · Pharvaris Netherlands B.V. · starts Oct 16, 2025
- Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE…NCT06919003 · Phase 2 · National Institute of Allergy and Infectious Diseases (NIAID) · starts Sep 22, 2025
- STOP-HAE: A Phase 3 Study of ADX-324 in HAENCT06960213 · Phase 3 · ADARx Pharmaceuticals, Inc. · starts Aug 28, 2025
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)NCT07021495 · Not reported · Leiden University Medical Center · starts Jul 29, 2025
Trials Authorized in Canada
The 10 newest of 41; search them all in Canada trials| Apr 7, 2026 | A phase 3 extension study of sirna targeting of prekallikrein with adx-324 in participants with hereditary angioedemaONVUZOSIRAN (ADX-324) | ADARX PHARMACEUTICALS, INC. | Pending |
| Dec 3, 2025 | An open-label study of donidalorsen in pediatric patients age 2 to less than 12 years old with hereditary angioedemaDONIDALORSEN (ISIS721744) | Ionis Pharmaceuticals | Closed |
| Sep 26, 2025 | Phase 3 trial to evaluate the long-term safety and efficacy of navenibart in participants with hereditary angioedema – orbit-expanseNAVENIBART | ASTRIA THERAPEUTICS, INC. | Ongoing |
| Sep 25, 2025 | A phase 3, randomized, double-blind, placebo controlled study of sirna targeting of prekallikrein with adx-324 in participants with hereditary angioedemaONVUZOSIRAN (ADX-324) | ADARX PHARMACEUTICALS, INC. | Ongoing |
| Jul 29, 2025 | An open-label study to provide berotralstat access to subjects with type i and ii hereditary angioedema who were previously enrolled in berotralstat studiesBEROTRALSTAT (BCX7353) | BioCryst Pharmaceuticals | Closed |
| Jul 10, 2025 | Post study access of csl312 (garadacimab) for the routine prevention of hereditary angioedema (hae) attacks in adult and adolescent participants (¿ 12 years…CSL312 (GARADACIMAB) | CSL | Pending |
| May 13, 2025 | Post study access of csl312 (garadacimab) for the routine prevention of hae attacks in pediatric participants (2-11 years old) with hereditary angioedema (hae)…GARADACIMAB (CSL312) | CSL | Ongoing |
| Mar 19, 2025 | Phase 3, multicenter, randomized, double-blind, placebo controlled trial to evaluate the efficacy and safety of navenibart in participants with hereditary…NAVENIBART (STAR-0215) | ASTRIA THERAPEUTICS, INC. | Ongoing |
| Jan 14, 2025 | A phase 4 open-label study to evaluate the safety after switching to csl312 (garadacimab) from current prophylactic hae treatment in subjects with hae ¿ 12…CSL312 (GARADACIMAB) (FACTOR XIIA ANTAGONIST MONOCLONAL ANTIBODY) | CSL | Closed |
| Oct 31, 2024 | Haelo: a phase 3, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ntla-2002 in participants with…NTLA-2002 | INTELLIA THERAPEUTICS, INC. | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 20| Dec 11, 2025 | Orladeyoprophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years of age and older | BioCryst Pharmaceuticals, Inc. | Approved |
| Aug 21, 2025 | Dawnzeraprophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older | Ionis Pharmaceuticals | Approved |
| Jul 3, 2025 | Ekterlytreatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older | KalVista Pharmaceuticals Ltd | Approved |
| Jun 16, 2025 | Andembryprophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older | CSL Behring | Approved |
| Feb 3, 2023 | Takhzyroprophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Dec 3, 2020 | ORLADEYO™prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older | BioCryst Pharmaceuticals, Inc. | Approved |
| Sep 24, 2020 | HaegardaHAEGARDA is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) (C1-INH) indicated for routine prophylaxis to prevent Hereditary… | CSL Behring LLC | Approved |
| Aug 23, 2018 | TakhzyroProphylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Jun 20, 2018 | CinryzeCINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric… | Takeda Development Center Americas, Inc. | Approved |
| Jun 22, 2017 | HaegardaFor routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult patients. | CSL Behring LLC | Approved |
| Jul 16, 2014 | RUCONESTTreatment of acute attacks of hereditary angioedema (HAE) in adult and adolescent patients. | Pharming Group N.V. | Approved |
| Mar 28, 2014 | KalbitorTreatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Aug 25, 2011 | FirazyrTreatment of acute attacks of hereditary angioedema in adults 18 years of age and older | Takeda Development Center Americas, Inc. | Approved |
| Dec 1, 2009 | KalbitorTreatment of acute attacks of hereditary angioedema in patients 16 years of age and older | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Oct 8, 2009 | BerinertTreatment of acute attacks of hereditary angioedema. | CSL Behring LLC | Approved |
Medicines Authorised in the EU
Newest first| Jan 19, 2026 | Dawnzeradonidalorsen | Otsuka Pharmaceutical Netherlands B.V. | EMA ↗ |
| Sep 17, 2025 | Ekterlysebetralstat · orphan | Kalvista Pharmaceuticals (Ireland) Limited | EMA ↗ |
| Feb 10, 2025 | Andembrygaradacimab | CSL Behring GmbH | EMA ↗ |
| Jul 16, 2021 | Icatibant Accordicatibant · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Apr 30, 2021 | Orladeyoberotralstat | Neopharmed Gentili Ireland Limited | EMA ↗ |
| Nov 22, 2018 | Takhzyrolanadelumab · orphan | Takeda Pharmaceuticals International AG Ireland Branch | EMA ↗ |
| Jun 15, 2011 | CinryzeC1 inhibitor (human) | Takeda Manufacturing Austria AG | EMA ↗ |
| Oct 28, 2010 | Ruconestconestat alfa | Pharming Group N.V. | EMA ↗ |
| Jul 11, 2008 | Firazyricatibant | Takeda Pharmaceuticals International AG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA